pancreatic-cancer

Repeated tumor ablation trains the immune system to attack pancreatic cancer — and reveals a targetable brake

Thermal ablation (using heat to destroy tumors) is gaining use in pancreatic cancer, but it has mostly been viewed as a local treatment. This study tested whether repeated radiofrequency ablation could trigger a systemic immune response — an 'abscopal effect' — where treating one tumor site helps the immune system attack tumors elsewhere.

Using a genetically engineered mouse model, the researchers found that serial ablation did generate a robust abscopal response, dependent on CD8 T cells and natural killer cells. Single-cell RNA sequencing then revealed the molecular bottlenecks limiting this immune activation — including a targetable immunosuppressive mechanism that, when blocked, enhanced the anti-tumor response.

For a disease as treatment-resistant as pancreatic cancer, demonstrating that ablation can prime systemic immunity and identifying how to amplify that response is clinically significant.

Key Findings

Serial radiofrequency ablation enhances local tumor control and triggers an abscopal immune response in PDAC
Abscopal effect is CD8 T cell-dependent (depleting CD8 cells abrogated the response)
Natural killer cells are activated as part of the systemic immune response
Single-cell RNA sequencing identified targetable immunosuppressive mechanisms
Combining ablation with immune checkpoint or other immune modulators could amplify response

Implications

This work provides a mechanistic basis for combining thermal ablation with immunotherapy in pancreatic cancer — a combination being tested in early clinical trials. Identifying the specific suppressive pathways revealed by single-cell sequencing gives immediate drug targets to test. Relevant for the ~30% of PDAC patients treated with ablation.

Caveats

Preprint — not peer reviewed. Based on abstract only. Mouse model (KPC flank tumors) may not fully recapitulate human PDAC biology. The specific targetable suppressive mechanisms identified need human validation. Translation from flank to orthotopic tumors and patients requires further study.

Source: bioRxiv — 2026-04-08

Landmark DCIS trial, CRC microbiome & AML combos

Two themes cut across this week’s 236 posts. The first is de-escalation: researchers are building rigorous evidence that patients can safely do less — skip lymph node surgery, forgo radiotherapy, watch pre-invasive lesions instead of cutting them out. The landmark result here is a randomized trial confirming that active surveillance

Colorectal Cancer Microbiome Discovery Platform

Analysis of 9,000+ patients revealed that only colorectal cancer — not other cancer types — consistently harbors distinct microbial communities, suggesting the gut microbiome has a unique relationship with colorectal carcinogenesis that could be exploited for diagnostics and treatment.

GBM Tumor Microenvironment Drug Target Atlas

Non-cancerous brain support cells were found to promote glioblastoma growth through paracrine signaling, and blocking this communication dramatically slowed tumor growth — revealing that GBM's microenvironment contains targetable vulnerabilities that are being systematically overlooked by drug…

BET Inhibitor Target Selectivity Database

BRD2 and BRD4 have fundamentally distinct functions — BRD2 prepares genes for activation while BRD4 triggers transcription — meaning that pan-BET inhibitors have been disrupting gene regulation in counterproductive ways, and the field now needs selective BRD4 inhibitors.